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African  horse  sickness  virus  (AHSV)  is  an  arthropod-borne  pathogen  that  infects  all species  of  equidae
and  causes  high  mortality  in horses.  Previously,  a recombinant  modiﬁed  vaccinia  Ankara  (MVA)  virus
expressing  the protein  VP2  of  AHSV  serotype  4 was  shown  to induce  virus  neutralising  antibodies  in
horses  and  protected  interferon  alpha  receptor  gene  knock-out  mice  (IFNAR  −/−) against  virulent  AHSV
challenge.
This study  builds  on  the  previous  work,  examining  the  protective  efﬁcacy  of  MVA-VP2  vaccination  in the
natural  host  of  AHSV  infection.  A study  group  of  4 horses  was  vaccinated  twice  with  a recombinant  MVA
virus  expressing  the  major  capsid  protein  (VP2)  of  AHSV  serotype  9. Vaccinated  animals  and  a control
group  of  unvaccinated  horses  were  then  challenged  with  a virulent  strain  of  AHSV-9.  The vaccinatedP2
rotection
animals  were  completely  protected  against  clinical  disease  and  also  against  viraemia  as  measured  by
standard  end-point  dilution  assays.  In  contrast,  all control  horses  presented  viraemia  after  challenge  and
succumbed  to the infection.
These  results  demonstrate  the  potential  of  recombinant  MVA  viruses  expressing  the  outer  capsid  VP2
of AHSV  as  a protective  vaccine  against  AHSV  infection  in  the  ﬁeld.
© 2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
African horse sickness (AHS) is a lethal arboviral disease of
quids with mortality rates that can exceed 95% in susceptible
opulations. The disease is endemic to sub-Saharan Africa but
poradically escapes from this geographical area and extends to
he North of Africa, the Middle East, the Arabian Peninsula, India
nd Pakistan. In the past, the disease has also spread to Europe,
peciﬁcally to Spain in 1969 and Spain and Portugal in 1987 [1,2].
he latest outbreak in Western Mediterranean countries lasted years [3,4].
To date no effective treatment exists for AHS and consequently
ontrol of the disease relies on preventive vaccination. AHS vac-
∗ Corresponding author. Tel.: +44 1483231081.
E-mail address: javier.castillo-olivares@pirbright.ac.uk (J. Castillo-Olivares).
ttp://dx.doi.org/10.1016/j.vaccine.2014.04.036
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
cines, based on attenuated AHS viruses, have been in use in South
Africa for almost 100 years and permitted the subsistence of horses
in that part of the world. There are nine different serotypes of
AHS virus (AHSV) and protective immunity is long-lived against
homologous serotypes. Thus, vaccination in endemic countries is
normally performed by administration of combinations of rep-
resentative attenuated strains of each of the virus serotypes.
Serotypes 5 and 9 are normally excluded from vaccine formula-
tions. Serotype 5 is difﬁcult to attenuate and partially cross-reacts
with serotype 8; and serotype 9 does not normally occur in South
Africa (the main AHSV vaccine manufacturing country) and par-
tially cross-reacts with serotype 6 [3,5,6].
Despite their apparent efﬁcacy, live AHSV vaccines have a num-
ber of disadvantages [4]. These include: (a) the risk of reversion to
virulence; (b) the risk of gene segment re-assortment between ﬁeld
and vaccine strains; (c) the risk of introducing foreign topotypes
into a new geographical region, since vaccines are based on South
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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frican strains; (d) the absence of DIVA (Differentiating Infected
rom Vaccinated Animals) capacity, that is the inability to serologi-
ally differentiate vaccine-induced immunity from that induced by
atural infection; and (e) the contra-indications for use in pregnant
ares because of their teratogenicity. In addition to these science-
ased shortcomings of the live vaccines it is also important to
onsider the potential logistical delays between the ﬁrst detection
f an outbreak and the deployment of sufﬁcient vaccine doses to
here they would be needed.
The recognised shortcomings of existing live AHSV vaccines
as meant that alternative vaccination strategies have been pur-
ued over the years. These have included the use of killed vaccines
7–9], vaccines based on baculovirus-expressed AHSV capsid pro-
eins [10], DNA vaccines [11] and those based on the use of poxvirus
xpression vectors [12–14]. The latter appear to be a particu-
arly promising strategy, which has started to produce encouraging
esults. We  have demonstrated recently that recombinant MVA
iruses expressing VP2 from AHSV serotype 4 (MVA-VP2), the
ajor capsid protein of AHSV and main target of virus neutral-
sing antibodies (VNAb), induced VNAb in horses and complete
rotection against virulent challenge in a mouse model [12,13].
These studies have now been extended to determine the protec-
ive capacity of MVA-VP2 vaccination against AHSV clinical disease
nd viraemia in the target species, the horse.
. Materials and methods
.1. Viruses
A recombinant MVA  expressing the VP2 protein of the AHSV-
 reference strain (PAKrrah/09), was generated using standard
ublished techniques [12,13,15] using primary chicken embryo
broblasts (CEF), obtained from the Microbiological Services of the
irbright Institute (MSPI). This virus was designated MVA-VP2(9).
he DF-1 cell line [16], obtained from MSPI and currently avail-
ble from the ATCC (CRL-12203) was used to grow the MVA-VP2(9)
irus, with an input multiplicity of infection (moi) of 0.1. When
aximum cytopathic effect (cpe) had been reached, the super-
atant media and cell debris were harvested and centrifuged at
30 × g, 4 ◦C. The low titre supernatant was discarded and the
ighly infective pellet was re-suspended in Dulbecco’s Modiﬁed
agle’s Essential Medium (DMEM) supplemented with penicillin-
treptomycin. The re-suspended pellet was titrated, stored at
70 ◦C, and used for vaccination after being diluted in DMEM.
The AHSV-9 challenge virus used was from the Orbivirus Refer-
nce Collection at Pirbright. It was a derivative of the AHSV-9 strain
EN2006/01, a ﬁeld isolate collected from a dead foal in Nairobi in
006. The virus was grown in Culicoides KC cells, titrated in Vero
ells by a standard end-point dilution assay, and subsequently pas-
aged in Vero cells. The ﬁnal titre of the virus, expressed as 50%
issue Culture Infective Dose (TCID50) per ml,  was 106.8
.2. Horses
For the study, a mixture of seven male and female cross-breed
orses of 1 year of age were used. The animals were randomly
ssigned to two different groups. Four were vaccinated with MVA-
P2(9) and three animals acted as non-vaccinated controls. Before
accination, horses were group housed outdoors for a quarantine
eriod. During this period, routine veterinary health checks were
erformed. One week before vaccination, the animals were moved
o the experimental facilities for acclimatization to the new envi-
onment. All sampling procedures and clinical examinations of the
nimals were performed by an experienced veterinary surgeon.2 (2014) 3670–3674 3671
Trained animal husbandry technicians were responsible for day-
to-day husbandry procedures.
This study was approved with the authorization number 339 by
the local Ethical Review Committee of Zoetis, Olot, Spain, in com-
pliance with national guidelines and EU regulations for projects
using animals for research purposes. The facilities and husbandry
procedures complied with the EU Directive 2010/63/EU.
2.3. Vaccination and challenge
Three animals were not vaccinated and acted as controls. The
remaining four horses received the MVA-VP2 (9) vaccine, with vac-
cine dose (108 pfu/ml) being split into an intramuscular (0.5 ml)  and
a subcutaneous (0.5 ml)  injection, both given on the side of the neck.
Vaccination was  on day 0 (V1), with a booster being administered
on day 20 (V2). The animals were challenged 14 days after the last
vaccination by intravenous injection (4 ml)  with a challenge dose
of 107.4 TCID50 per horse. Horses were clinically examined twice
a day following infection with AHSV-9 and more often once clini-
cal signs began to develop. Clinical signs and rectal temperatures
were recorded. Humane end-points established for this experi-
ment included any of the following: presence of severe generalised
oedema, severe dyspnoea, presence of foamy nasal exudate, severe
depression with prostration or high rectal temperatures (above
40 ◦C) for four consecutive days.
2.4. Sample collection
Blood samples for serological analysis were collected on days 0
(V1), 6, 13, 20 (V2), 27 and 34 (challenge). Blood samples for virus
isolation and RT-PCR were collected on day 34 (challenge day) and
days 3, 7, 9, 11, 14, 17 and 21 post-challenge.
2.5. Serology
To measure VNAb, serum samples were ﬁrst inactivated at 56 ◦C
for 30 min  and then titrated in a 96-well ﬂat-bottomed tissue cul-
ture plate. Standard published methods were followed [13,17].
Brieﬂy, each dilution was  incubated with 100 TCID50 of the AHSV-9
virus, incubated for 4 days and end-points deﬁned as the dilution
that neutralised virus infectivity of 50% of the replicates. Titres were
calculated according to Karber [18].
Serum samples were also analysed using a VP7 ELISA test to
determine the antibody responses speciﬁc for this AHSV antigen.
The INGEZIM VP7 ELISA (Ingenasa, Madrid, Spain) was  used accord-
ing to the manufacturer’s protocol.
2.6. Virus isolation and real time RT-PCR
Blood samples were processed as previously described [12].
The treated samples were serially diluted, in triplicate, on a micro
titre plate and each sample incubated with 100 l/well of a cell
suspension containing 105 Vero cells/ml. After 4 days incubation
the highest sample dilution causing cytopathic effect in 50% of
the replicate wells was recorded and the Tissue Culture Infectious
Dose 50 (TCID50) of the sample calculated according to Karber:
Log10TCID50 = a − D (Sp − 0.5), where a is the log10 of highest dilu-
tion giving 100% cpe; D is the log10 of the dilution factor; Sp is the
sum of the fractions of cpe-positive replicates; and 0.5 is a constant.
The ﬁnal viraemia results were expressed as TCID50/ml  of blood.
Real time RT-PCR was performed according to published proce-
dures [19]. Brieﬂy, viral RNA was extracted from blood samples
using the BioSprnt 96 DNA Blood kit (QIAGEN) following man-
ufacturer’s instructions. A known concentration of a synthetic
double-stranded RNA from the viral RNA segment encoding VP7
was used as a standard to quantify the viral genome copies. This
3672 B. Alberca et al. / Vaccine 3
F
h
s
(
g
t
s
K
R
b
s
p
c
i
a
s
s
3
3
d
a
i
3
w
3
r
w
c
w
T
V
c
–ig. 1. Individual rectal temperatures of vaccinated (V1–V4) and control (C1–C3)
orses recorded over the whole study period.
ynthetic double stranded RNA was generated using a pMA  plasmid
Life Technologies) coding for a 107 bp fragment from AHSV-VP7
ene ﬂanked on both sides by T7 polymerase promoters. For
he generation of the double-stranded RNA (dsRNA), both RNA
trands were transcribed in vitro using the MEGAshortscriptTMT7
it (Ambion) following manufacturer instructions. Transcribed
NAs were puriﬁed using the MEGAclearTM kit (Ambion), checked
y agarose gel electrophoresis and concentration determined by
pectrophotometry. Transcribed ssRNA molecules were mixed in
recise equimolar amounts. This dsRNA was adjusted to 7.2 × 107
opies/l. Serial ten-fold dilutions of the standard RNA were
ncluded in each assay. Cycle Threshold (Ct) values were plotted
gainst the serial dilutions of the standard RNA to produce the
tandard curve to determine the genome copies per ml  of blood
ample.
. Results
.1. Immunogenicity of MVA-VP2(9)
All horses were sero-negative at the beginning of the study and
eveloped serum VNAb upon inoculation with MVA-VP2(9). No
dverse reactions to vaccination were seen, other than a transient
nﬂammation at the injection site which subdued after 24 h. On day
4 of the study, the vaccinated horses and 3 unvaccinated controls
ere challenged with AHSV-9.
.2. Clinical signs and pathology
Following challenge with AHSV-9, all vaccinated animals
emained clinically normal and their rectal temperatures remained
ithin physiological ranges until the end of the study (Fig. 1). In
ontrast, all the control horses developed clinical signs consistent
ith the cardiac form of African horse sickness. They became febrile
able 1
iraemia- end-point dilution assay: results of the microtitrevirus plaque assays perform
hallenge with AHSV-9. The results are expressed as (log10TCID50/ ml  of blood) of individ
Group Horse Day 0 Day 3 Day 5 
Vaccine MVA-VP2 (9) V1 – – – 
V2  – – – 
V3  – – – 
V4  – – – 
Controls C1  – 4.6 5.5 
C2  – 4.5 5.8 
C3  – 4.5 5.8 
: Negative result.
* ns: No sample.2 (2014) 3670–3674
by day 2 post-infection as rectal temperatures reached values ran-
ging between 39.08 to 39.28, a signiﬁcant rise compared with the
vaccinated group (Wilcoxon rank sum test: P = 0.05). These tem-
peratures peaked on day 3 (horse C3) and day 4 (horses C1 and
C2), and then declined in the hours before death. Clinical signs in
the control animals were present by day 3 post-infection and com-
prised: mild general malaise and depression; palpebral oedema
and conjunctivitis; and mild nasal discharges. These clinical signs
slightly worsened on day 4 and progressed very rapidly thereafter.
The three control horses died between the end of day 5 (C3) and
day 6 (C1 and C2).
The post-mortem lesions of control horses were consistent
with the cardiac form of AHS, and included: oedema, congestion
and haemorrhages of the ocular conjunctiva; the presence of a
yellow gelatinous oedema in the inter-muscular fasciae of the
neck and sub-scapular region, oesophagus and epicardial surfaces;
hydropericardium; hydrothorax; sub-endocardial haemorrhages;
and congestion of the kidneys, liver, spleen and stomach mucosa.
The lungs presented mildly enlarged interlobular septi but the typ-
ical frothy ﬂuid of the ‘pulmonary form’ of AHS was  not present.
3.3. Viraemia and real time RT-PCR
The results of these tests are presented in Tables 1 and 2. All vac-
cinated animals were negative for infectious virus in blood whereas
the control horses developed viraemia with viral titres that ranged
between 104.5 to 104.6 TCID50/ml  on day 3, and between 105.5 to
105.8 TCID50/ml  on day 5. The differences between vaccinates and
controls on each day were statistically signiﬁcant (Wilcoxon rank-
sum test: P = 0.03 for both days)
Real time RT-PCR results indicate that there were signiﬁcant
differences in the viral load between vaccinates and controls. The
mean viral RNA log10 copy number on day 3 was 106.8 for controls
and 102.9 for vaccinated animals (Wilcoxon rank-sum test P = 0.06),
while on day 5 it was  107.8 for controls and 101.6 for vaccinated
animals (Wilcoxon rank-sum test P = 0.05). The vaccinated animals
remained positive by RT-PCR on subsequent days post-challenge
and some animals that were negative produced a positive result on
later samples. By day 21, vaccinated horses were still positive by RT-
PCR although infectious virus was  undetectable by the end-point
dilution assay.
3.4. Antibody responses following MVA-VP2(9) vaccination and
AHSV-9 challenge
As expected, all four animals vaccinated with MVA-VP2(9)
developed VNAb by the time of challenge with titres ranging
between 1.6 to 2.4 (Table 3). Following AHSV-9 challenge these
VNAb titres increased more than four-fold in all four animals and
the ﬁnal titres recorded on day 28 post-challenge reached values of
between 2.3 to more than 3.1. All non-vaccinated control horses
ed on blood samples collected from the vaccinated and control horses following
ual samples.
Day 7 Day 9 Day 11 Day 14 Day 17 Day 21
– – – – – –
– – – – – –
– – – – – –
– – – – – –
ns* ns ns ns ns ns
ns ns ns ns ns ns
ns ns ns ns ns ns
B. Alberca et al. / Vaccine 32 (2014) 3670–3674 3673
Table  2
Viraemia—RT-PCR: results of the RT-PCR assay for the detection of viral RNA from blood samples collected from vaccinated and control horses challenged with AHSV-9. The
results  are expressed as RNA copy numbers (log10) per ml  of blood of individual samples.
Group Horse Day 0 Day 3 Day 5 Day 7 Day 9 Day 11 Day 14 Day 17 Day 21
Vaccine MVA-VP2 (9) V1 – 2.73 2.82 3.44 3.76 2.92 4.83 5.41 5.16
V2  – 2.72 – – – 3.04 3.6 4.01 3.09
V3  – 3.09 – – 5.78 – 2.7 2.66 2.81
V4  – 2.97 3.51 4.03 5.29 6.21 6.1 5.63 4.93
Controls C1  – 6.95 7.76
C2 – 6.38 7.81
C3 – 7.07 7.94
–: Negative result.
Table 3
VNAb titres (log10) of serum samples collected from vaccinated and control horses.
Group Horse Day 0 Day 34 (challenge) Day 62
Vaccine
MVA-VP2(9)
V1 − 1.6 2.3
V2 − 2.4 >3.1
V3 − 1.8 2.68
V4 − 1.8 >3.1
Controls C1  − − *ns
C2 − − ns
C3  − − ns
−
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* ns: No sample.
ere negative for VNAb at virus challenge and did not develop
NAb before they succumbed to AHSV-9 infection.
Antibodies to AHSV-VP7 were detected in serum samples of the
accinated horses only after challenge (Table 4). As expected all
orses were negative by the VP-7 ELISA test on the day of challenge
day 34).
. Discussion
This study in the disease relevant host, the horse, was aimed
t determining the protective capacity of vaccines based onMVA-
P2 against virulent AHSV challenge. This work focused on AHSV-9.
hus, the MVA-VP2(9) recombinant vaccine was constructed using
he genome segment encoding VP2 from the AHSV-9 reference
train (PAKrrah/09) and vaccinated animals were challenged with
he AHSV-9 strain KEN/2006/01.
Ponies immunised with MVA-VP2(4) in a previous study [13]
nd those vaccinated with MVA-VP2(9) in this study developed
NAb titres after two doses and reached titres against homologous
irus, ranging between 1.8 to 1.9 or between 1.6 to 2.4, respec-
ively. These results are in line with studies by others using poxvirus
ectors expressing AHSV-VP2. Thus, horses vaccinated with 107.1
CID50 of a canarypox-based AHSV vaccine [14] expressing VP2 and
P5 developed serum VNAb titres of 20–40 (1.3–1.6 log10); and use
f a recombinant vaccinia virus (strain WR)  expressing AHSV-4 VP2
able 4
P7-speciﬁc antibody levels, measured by the VP-7 ELISA test, of serum samples
ollected from vaccinated and control horses. Figures represent the percentage of
ntibody binding inhibition of a VP7-speciﬁc antibody to the VP7 antigen for each
f  the serum samples analysed. Positive VP-7 speciﬁc antibody levels are indicated
n  bold.
Group Horse Day 0 Day 34 (challenge) Day 62
Vaccine
MVA-VP2(9)
V1 Not done 37.20 55.76
V2 Not done 23.69 79.43
V3 Not done 27.13 65.52
V4 Not done 29.43 76.10
Controls (AHV9) C1 Not done 29.68 *ns
C2 Not done 32.66 ns
C3 Not done 29.31 ns
* ns: No sample.also induced VNAb in horses [20], albeit at low titres and only after
3 vaccine inoculations.
In this study, vaccination of horses with MVA-VP2(9) showed
very high levels of protection despite the high challenge virus
dose used. Clinical signs were completely absent in vaccinates
and the rectal temperatures were within normal physiological
ranges during the study period. In contrast, the control horses
experienced a peracute AHSV cardiac syndrome accompanied by
high rectal temperatures. Vaccinated animals were also completely
protected against viraemia as measured by a standard end-point
dilution assay demonstrating the potential of MVA-VP2 vaccina-
tion to prevent onward transmission by the insect vectors. These
levels of protection are in line with those of other vaccination
approaches [6,14], although the mechanisms of immunity through
which vaccine protection was exerted might be different. The cur-
rent live attenuated vaccines induce a low VNAb titre in vaccinates
after a primary vaccination course suggesting cell-mediated immu-
nity plays an important role in clearance of AHSV infection in
horses vaccinated with live attenuated or canarypox VP2/VP5 vac-
cines [6,14,21]. In the mouse model both cell-mediated and VNAb
responses were stimulated by MVA-VP2 vaccination, however pas-
sive transfer experiments have shown that humoral immunity
plays a critical role in protection against AHSV [12,22]. In the
present study, MVA-VP2 vaccination induced a relatively high
VNAb titre compared to that induced by existing live attenuated
vaccines, but cell-mediated immune responses have not yet been
measured.
In this study we  have detected the presence of viral RNA, though
at lower levels than in the control animals, in non-infectious blood
samples from the vaccinated horses for up to day 21 post-challenge.
The high virus challenge dose (107.4 per horse) given by the intra-
venous route, the natural capacity of AHSV to bind erythrocytes
[23] and the high sensitivity of RT-PCR techniques could explain
the presence of viral RNA in the non-infectious blood of vacci-
nated horses. This is consistent with the ﬁndings obtained during
the development of an RT-PCR diagnostic assay of AHSV in which
viral RNA was detected from the blood of horses inoculated intra-
venously with 105.5 TCID50/ml  up to day 97 post-infection [24]. It
is very difﬁcult to discern from our data whether AHSV RNA in the
vaccinates was a result of viral replication in the host or not. Anal-
ysis of the antibody responses by the virus neutralisation test and
by the VP7 ELISA test showed more than a four-fold increase in
VNAb titre and an increase in VP7 ELISA antibody levels in paired
serum samples collected at day 34 (challenge day) and day 62. This
could be an indication of a low level of viral replication in the vac-
cinates but this could also be the result of an anamnestic response
of immune animals to re-exposure to an AHSV antigenic stimulus.
Alternatively, virus particles neutralised by serum antibodies, could
still be circulating in the vaccinates and could have been the source
of viral RNA detected by the RT-PCR assay. Further work is needed to
elucidate whether MVA-VP2 vaccination induces a complete sterile
immunity but from the results of our study this immune response
was sufﬁcient to abrogate AHSV infectivity and to prevent any
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linical disease and pyrexia in horses challenged with a high dose
f AHSV.
This study has demonstrated that MVA  vaccines expressing
P2 alone are capable of inducing protective immunity, showing
hat co-expression of VP5 or other capsid proteins is not essen-
ial for the induction of a protective response. Other studies using
HSV-VP2 based vaccines, using baculovirus expression, plasmid
NA or replication-competent vaccinia virus vectors, showed that
P2 alone can induce VNAb and protective immunity in horses
11,20,25]. However, other studies showed that co-expression of
P5 seemed to improve immunogenicity of VP2-based recombi-
ant vaccines [14,26]. It is possible therefore, that co-expression
f VP2 and VP5 from the same MVA  recombinant vaccine vector
esults in improved immunogenicity.
The MVA-VP2 vaccination approach has worked with AHSV
erotypes 4 and 9, and other recombinants expressing the AHSV-
P2 from other serotypes can be easily constructed to generate the
omplete set of monovalent AHSV vaccines based on MVA.
AHS is a lethal disease of horses that currently causes severe
nimal and economic loses in Africa and has the capacity to spread
o Europe, as has been seen with bluetongue in the recent past. The
rimary way of controlling this disease currently is by the use of
he live attenuated vaccines, which are regarded as unsuitable for
on-endemic countries for biosafety reasons. Our results indicate
hat the MVA-VP2 vaccine strategy is highly protective, and is com-
atible with a DIVA (differentiation of infected against vaccinated
nimals) strategy. This feature would prevent the spread of AHSV
utbreaks in non-endemic countries without compromising sero-
urveillance and would enable a ‘vaccination to live’ policy to be
dopted as the vaccine allows for the demonstration of disease-free
tatus by serological discriminatory diagnostic tests (VP7 ELISA).
n our study, we used the VP7 ELISA, the Ofﬁce Internatinal des
pizooties (OIE) prescribed serological test for international trade,
nd showed that infection of MVA-VP2 vaccinated animals could
e detected by using this assay, showing that horses within an
HSV-risk area could potentially be vaccinated with MVA-VP2 and
he spread of AHSV infection could still be tracked by serological
creening of vaccinated animals. In addition, MVA-VP2 vaccination
ould also be used in endemic countries to control AHS since it
ould prevent disease and transmission and would facilitate, due
o its differential diagnostic capability, the movement of equids
etween different AHSV controlled geographical regions. The use
f this DIVA compatible vaccination approach could also facilitate
nternational trade of horses from the African continent.
In conclusion, we have demonstrated the potential of MVA-VP2
accination as a valid strategy for the prevention of AHS. The results
btained are very encouraging and the prospects of using a vaccine
hat is protective, safe and effective and that can be used both in
ndemic and non-endemic areas deserve further investigation.
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